Biotech investors waiting for partnership announcements
Shares of PharmaGap (TSX: V.GAP) rallied 31% to 19 cents on Wednesday.
Small biotech stock pops on FDA approval
Shares of Nuvo Research (TSX: T.NRI) shot up 30% to 45 cents on Thursday as the drug development company and Covidien (NYSE: COV) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid Topical Solution (diclofenac sodium topical solution) 1.5% w/w. Pennsaid Topical Solution is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of the signs and symptoms of osteoarthritis of the knee.
Mask supplier surges on contract news
Noveko (TSX: T.EKO) shares shot up 39 cents or 17% to $2.68 at last check.
SemBioSys (SBS) awarded U.S. patent
In breaking news Thursday, Calgary-based SemBioSys Genetics (TSX: T.SBS) announced that it has been granted a U.S. patent for a method for the commercial production of insulin in plant seeds.
Pharma firm surges on FDA news
Shares of Angiotech Pharmaceuticals (TSX: T.ANP) surged more than 48% to $2.87 Monday, as the Vancouver-based company announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Option Inferior Vena Cava Filter in the United States.
Biotech firm set to start modified Phase II stroke trial
Calgary-based Stem Cell Therapeutics Corp. (TSX: V.SSS) announced Thursday that it has decided to start the modified Phase IIb REGENESIS clinical stroke trial as soon as possible, with the goal of completing patient enrollment by the end of 2009.
Noveko tests masks for use against H1N1
Noveko International (TSX: T.EKO) shares were up 12.5% to $2.42 Tuesday, after the air filter, face mask and antimicrobial product developer announced that it has received preliminary results of tests on the Noveko antimicrobial masks with respect to the Influenza A Virus (H1N1), similar to the one responsible for the human swine flu.
Q3 results in for Bioniche Life Sciences
Ontario-based Bioniche Life Sciences (TSX: T.BNC) reported its financial results for the third quarter of its 2009 fiscal year Wednesday, including revenue of $7.4 million.
U.S. biotech swine flu stocks tumble
Several U.S. biotech stocks fell Wednesday, after recording significant gains earlier in the week on swine flu concerns.
